文献速递脑血管病外科神经重症

静脉米力农时代动脉瘤性蛛网膜下腔出血后严重迟发性脑缺血风险降低

Decreased Risk of Severe Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage in the Era of Intravenous Milrinone.
PubMed 文献 · World Neurosurg · 2026-05-25

该回顾性队列研究纳入2016至2024年619例aSAH患者,其中230例存在中重度血管造影脑血管痉挛,27%接受静脉米力农。倾向评分匹配后,米力农组DCI相关梗死发生率低于对照组(6.3% vs 24%,P=0.006),多因素回归aOR 0.08(95%CI 0.02-0.42)。

要点

  • 血管造影发现中重度CVS后使用静脉米力农与DCI梗死风险显著降低相关。
  • Hunt-Hess 4-5级患者中米力农组DCI相关死亡率低于对照组(4% vs 32%,P=0.03)。
  • 严重CVS患者接受米力农后需额外血管成形术的比例更低(5.3% vs 37.5%,P=0.03)。

核心结论

  • 静脉米力农时代,aSAH后中重度血管造影CVS患者发生DCI相关梗死及对内血管治疗难治的DCI风险更低。

研究设计与样本

  • 回顾性机构数据库研究,检索2016至2024年aSAH患者,筛出中重度血管造影CVS者,按是否接受静脉米力农分组,经倾向评分匹配后比较结局。

主要发现

  • 619例aSAH中37%(n=230)存在中重度血管造影CVS,其中27%(n=63/230)接受静脉米力农。
  • 米力农组中78%有症状,30%初始为严重CVS需血管成形术。
  • 匹配后米力农组后续DCI梗死发生率6.3%,对照组24%(P=0.006)。
  • 多因素回归显示米力农与DCI梗死发生率降低独立相关(aOR 0.08,95%CI 0.02-0.42)。
  • Hunt-Hess 4-5级患者中米力农组DCI相关死亡率4%,对照组32%(P=0.03)。

临床怎么用

  • 对于aSAH后血管造影证实中重度CVS的患者,可考虑静脉米力农以降低DCI相关梗死风险。
  • Hunt-Hess 4-5级及初始严重CVS需血管成形术者可能从静脉米力农中额外获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The efficacy and optimal timing of intravenous (IV) milrinone for cerebral vasospasm (CVS) has not been definitively established. The purpose of this study was to investigate the effect of IV milrinone on delayed cerebral ischemia (DCI) when angiographic CVS was detected. METHODS: An institutional database of aSAH was queried for moderate or severe angiographic CVS from 2016 to 2024. Patients were classified into those who received IV milrinone and those who did not. After propensity score matching, study outcomes included DCI-related infarct, additional angioplasty, recurrent CVS requiring ≥3 subsequent endovascular treatments, and mortality. Effect sizes were adjusted in multiple regression and subgroup analyses. RESULTS: Among 619 patients with aSAH, 37% had moderate or severe angiographic CVS (n = 230). IV milrinone was administered in 27% of patients (n = 63/230). Of these patients, 78% were symptomatic, and 30% had initially severe CVS requiring angioplasty. Compared to baseline-matched patients, those who received IV milrinone had a lower incidence of subsequent DCI infarct (6.3% vs. 24%, P = 0.006). In multiple regression, IV milrinone was associated with a significantly decreased incidence of DCI infarct (aOR 0.08, 95%CI 0.02-0.42). DCI-related mortality was decreased in Hunt-Hess 4-5 patients on milrinone (4% vs. 32%, P = 0.03). Patients with severe CVS who received IV milrinone required less additional angioplasty than those who did not (5.3% vs. 37.5%, P = 0.03). CONCLUSION: This study provides evidence that there is a lower risk of cerebral infarcts and DCI refractory to endovascular treatment in the era of IV milrinone.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Ma L, Agarwal P, Jacobs RC, et al. Decreased Risk of Severe Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage in the Era of Intravenous Milrinone. World Neurosurg. 2026. PMID: 42190984. doi:10.1016/j.wneu.2026.125081

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。